QSAR studies in substituted 1,2,3,4,6,7,12,12a-octahydropyrazino[2′,1′:6,1]pyrido[3,4-b] indoles - A potent class of neuroleptics

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 9, 2003, Pages 2085-2090

  Saxena, Anil K ^a   Ram, Siya ^a   Saxena, Mridula ^a   Singh, Nidhi ^b   Prathipati, Philip ^a   Jain, Padam C ^a   Singh, H K ^a   Anand, Nitya ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b PDEA's Seth Govind Raghunath Sable College of Pharmacy   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CENTBUTINDOLE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; INDOLE DERIVATIVE; NEUROLEPTIC AGENT; SEROTONIN 2 ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONTINGENCY TABLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION FUNCTION; DIPOLE; DRUG POTENCY; DRUG SYNTHESIS; EMPIRICISM; HYDROPHOBICITY; LIPOPHILICITY; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MATHEMATICAL PARAMETERS; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; STIMULATION; SUBSTITUTION REACTION; THEORETICAL MODEL;

EID: 0037401361     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00652-1     Document Type: Article

References (33)

1. Reynold G.P. Trends Pharmacol. Sci. 13:1992;116.
2. Sedvall G., Farde L. Lancet. 846:1995;743.
3. Fleischhacker W.W. Acta. Psychiatr. Scand. Suppl. 388:1995;24.
4. Dubovsky S.L., Thomas M. J. Clin. Psychiatry. 56(suppl 2):1995;38.
5. Cox P.A. Symp. 185:1994;25.
6. Muramatsu M., Okuyama S., Tanaka M. Nippon Yakurigaku Zasshi. 104:1994;189.
7. Meltzer H.Y. Psychiatr. Clin. North Am. 16:1993;365.
8. Agnati L.F., Fuxe K., Benfenati F., von Euler G., Fredholm B. Neurochem. Int. 22:1993;213.
9. Marciniak B.H., Guay D.R.P. Consult. Pharm. 10:1995;1374.
10. Lindstorm L.H. Trends Pharmacol. Sci. 21:2000;198.
11. Meador-Woodruff J.H. Ann. Clin. Psychiatry. 6:1994;79.
12. Hietala J. Lancet. 346:1995;1130.
13. (a) Janssen P.A., Niemegeers J.E., Awouters F., Schellekens K.H.L., Megens A.A.H.P., Meert T.F.J. J. Pharmacol. Exp. Ther. 244:1988;685
14. (b) Leysen J.E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J.C., Janssen P.A.J. J. Pharmacol. Exp. Ther. 247:1988;661.
15. Balsara J.J., Jadhav J.H., Chandorkar A.G. Psychopharmacology. 22:1979;67.
16. Saxena A.K., Jain P.C., Anand N., Dua P.R. Drugs Future. 3:1978;803.
17. (a) Seeman P., Westman K., Protiva M., Jilek J., Jain P.C., Saxena A.K., Anand N., Humber L., Philipp A. Eur. J. Pharmacol. 56:1979;247
18. (b) Gulati A., Srimal R.C., Dhawan B.N. Pharmacology. 36:1988;396
19. (c) Saxena, A. K. unpublished work.
20. Saxena A.K., Jain P.C., Anand N., Dua P. R., Indian Journal of Chemistry. 11:1973;417.
21. Saxena A.K., Jain P.C., Anand N., Dua P.R. Indian Journal of Chemistry. 22B:1983;1224.
22. Saxena A.K., Agarwal S.K., Dhaon M.K., Kumar N., Prasad C.R., Nitya A., Jain P.C. Eur. J. Med. Chem.-Chem. Ther. 17:1982;4. 312.
23. Saxena A.K., Jain P.C., Anand N., Dua P.R., Anand N. J. Med. Chem. 16(5):1973;560.
24. Kaufman J.J., Koshi W.S. Physiochemical, Quantum Chemical and other Theoretical Techniques for the Understanding of the Mechanism of Action of CNS Agents: Psychotic Drugs, Narcotics and Narcotic Antagonists and Anesthetics. Ariens E.J. Drug Design. 1975;251 Academic Press, New York.
25. Courriere Ph., Paubel J.P., Niviere P., Blanpin O.F. Eur. J. Med. Chem. 13:1978;21.
26. Schaper K.J. Quant. Struct. Act. Relat. 18:1999;354.
27. Kumar N., Jain P.C. Progress in Drug Research. 21:1977;410.
28. Synder S.H., Horn A.S. Proc. Natl. Acad. Sci., U.S.A. 68:1971;2325.
29. Leo A., Hanch C., Elkins D. Chem. Rev. 71:1971;525.
30. Hanch C., Leo A., Unger S.H., Kim K.H., Nikaitani D., Lein E.J. J. Med. Chem. 16:1973;7207.
31. Cook W.J., Weidley E. Ann. N. Y. Acad. Sci. 66:1957;740.
32. Labute, P. MOE LogP(Octanol/Water) Model. Unpublished source code in $MOE/lib/svl/ quasar.svl /q_logp.svl 1998.
33. Wildman S.A., Crippen G.M. J. Chem. Inf. Comput. Sci. 39(5):1999;868.